Phase 4 Haemophilia Trial, Recruiting NCT07406139 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Haemophilia
Back to Haemophilia

Phase 4 Haemophilia Trial, Recruiting

NCT07406139
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with hemophilia A with inhibitors (where the body's immune system blocks the clotting treatment). People who have previously had high levels of inhibitors must still have a detectable inhibitor level at the time of enrollment (confirm with trial site for specific measurements)
  • People aged between 12 and 65 years
  • People who have had at least three bleeding episodes into their joints in the past six months
  • People who have signed a consent form agreeing to take part

Who may not be able to join:

  • People who have any other bleeding disorder, whether they were born with it or developed it over time
  • People whose liver or kidney function test results are above a certain level, as shown in recent blood tests (confirm with trial site for specific values)
  • People who are currently receiving a treatment called immune tolerance induction (ITI) therapy and whose inhibitor levels are below a certain threshold at the time of enrollment (confirm with trial site)
  • People who have previously had a blood clot (such as a deep vein thrombosis, stroke, or similar event)
  • People who have a known history of drug allergies, asthma, hives, or other significant allergic conditions
  • People whom the trial doctor considers unsuitable for participation, for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +8615620988690

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
20 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Efficacy of prothrombin complex concentrate (PCC) in the treatment of bleeding episodes in patients with hemophilia A with inhibitors.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov